Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KC7F2 是缺氧诱导因子HIF-1通道抑制剂,在 LN229-HRE-AP 细胞中的IC50=20 μM,可用作抗癌试剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 319 | 现货 | ||
10 mg | ¥ 463 | 现货 | ||
25 mg | ¥ 792 | 现货 | ||
50 mg | ¥ 1,380 | 现货 | ||
100 mg | ¥ 2,360 | 现货 | ||
200 mg | ¥ 3,520 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 397 | 现货 |
产品描述 | KC7F2 is a potent HIF-1 pathway inhibitor with potential anti-cancer activity. |
靶点活性 | HIF-1α:20 μM |
体外活性 | KC7F2 inhibits HRE-driven transcription and decreases HIF-1α protein levels in LN229-HRE-AP cells. KC7F2 shows a dose-response cytotoxicity with IC50 of approximately 15 to 25 μM in cancer cells MCF7, LNZ308, A549, U251 mg, and LN229. In D54 mg glioma cells, KC7F2 inhibits colony formation, especially under hypoxia. [1] In hypoxic microglial cultures, KC7F2 downregulates the expression of TfR and DMT, and reduces the HIF-1α mediated iron accumulation. [2] |
体内活性 | KC7F2 significantly reduces the latent period in the pentylenetetrazole kindling rat model and increases the rate of spontaneous recurrent seizures during the chronic stage in the lithium-pilocarpine rat model. [3] |
激酶实验 | HIF transcriptional activity assay: Cells are incubated at 37 in a humidified atmosphere containing 5% CO2 and 21% O2 (normoxia) or 1% O2 (hypoxia) in a hypoxia workstation. The LN229-HRE-AP reporter cell line for HIF transcriptional activity is created by stably transfecting LN229 cells with the pACN188 plasmid, which contains an alkaline phosphatase gene driven by six HREs derived from the VEGF gene. |
细胞实验 | Cells are seeded onto 96-well plates (4 × 103/well) and cultured under normoxic (21% O2) and hypoxic (1% O2) conditions with different concentrations of KC7F2 for 72 h or treated for various times with 20 μM KC7F2. For proliferation analysis, cells are fixed with 50% trichloroacetic acid for 1 h at 4°C, followed by staining with 0.4% sulforhodamine B dissolved in 1% acetic acid for 30 min at room temperature. Plates are washed five times with 1% acetic acid to remove unbound dye. Bound dye is dissolved by adding 10 mM unbuffered Tris base. Cell proliferation is calculated by measuring OD values at 564 nm using a spectrophotometer.(Only for Reference) |
分子量 | 570.38 |
分子式 | C16H16Cl4N2O4S4 |
CAS No. | 927822-86-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 57 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7532 mL | 8.7661 mL | 17.5322 mL | 43.8304 mL |
5 mM | 0.3506 mL | 1.7532 mL | 3.5064 mL | 8.7661 mL | |
10 mM | 0.1753 mL | 0.8766 mL | 1.7532 mL | 4.383 mL | |
20 mM | 0.0877 mL | 0.4383 mL | 0.8766 mL | 2.1915 mL | |
50 mM | 0.0351 mL | 0.1753 mL | 0.3506 mL | 0.8766 mL | |
100 mM | 0.0175 mL | 0.0877 mL | 0.1753 mL | 0.4383 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KC7F2 927822-86-4 Angiogenesis Chromatin/Epigenetic Metabolism HIF/HIF Prolyl-Hydroxylase HIF HIFs Inhibitor Hypoxia-inducible factors inhibit HIF-PH KC-7F2 inhibitor